Form 4: Bionano Genomics Director Receives Stock Option Grant

Director Yvonne Linney was granted 9,149 stock options in Bionano Genomics, Inc. as part of equity compensation.

Summary

• Director Yvonne Linney received a grant of 9,149 stock options on May 14, 2026.
• The options have an exercise price of $1.19 per share.
• The options are set to expire on May 13, 2036.
• Vesting occurs in equal monthly installments over 12 months, with full vesting guaranteed by the next annual stockholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational or financial trajectory.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Vesting is subject to the director's continuous service with the company.

Future Outlook

The options vest over 12 months or upon the next annual stockholder meeting, indicating a short-term retention and compensation structure for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though they contribute to ongoing share dilution.

Comparison to Industry Standards

• The use of monthly vesting schedules is consistent with standard corporate governance practices for board compensation in small-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new options.

Next Steps

• Vesting of options over the next 12 months
• Potential exercise of options by the director after vesting

Key Dates

Keywords

Bionano Genomics, BNGO, Director Compensation, Stock Options, Insider Transaction, Form 4